NotíciasBenzingaIonis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In... Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In... Benzinga 2026.09.23 08:51 (GMT+0) Abrir em Benzinga Outras notícias Hexcel é promovida pela Seaport com perspectiva de crescimento na defesa UBS inicia cobertura da Protagonist Therapeutics com recomendação de compra UBS inicia cobertura da Spyre com recomendação de compra pelo potencial em DII TotalEnergies e KKR adicionam portfólio solar de 700 MW à joint venture nos EUA Helikon eleva participação na Resolute Mining para 20,1% TotalEnergies e KKR ampliam joint venture solar nos EUA com 700 MW
